PRKN and Parkinson disease: For instance, the parkin Q311X mutation present in a subset of Parkinson's disease patients reduces the turnover of parkin‐interacting substrate (PARIS), relieving its transcriptional repression of PGC1‐(alpha), and thus downregulating TFEB and suppressing TFEB‐facilitated mitophagy (Siddiqui et al, 2015).